Your browser does not support iframes.
Data presented during the week of 70th World Health Assembly, in Geneva, placed a spotlight on an emerging global public healthcare challenge – the growing burden of managing multiple chronic conditions. The data, presented to a group of renowned public healthcare experts, convened by the International Association of Patient Organizations (IAPO) and Teva, showed a worrying gap in understanding and planning of the management of patients diagnosed with multiple chronic conditions (polychronic).
As the population ages, there is a rising tide of patients struggling with more than one disease. Treatment of these patients is more complex and costly, straining the healthcare system with potential adverse drug-drug interactions, falling treatment adherence, and higher hospital re-admittance rates .
Among the key insights:
“For the patient, this doesn’t mean just taking more medications, it means dealing with a variety of healthcare specialists who need to ensure they are providing well-coordinated care. That’s challenging for healthcare systems focused on targeting specific diseases.” Said Dr Cother Hajat Director, former Director of Global Health Strategy, The Vitality Group, one of the expert presenters at the meeting.
“There is a unique role that industry can play in helping to find solutions to this growing public health challenge. Teva is committed to playing its part. We can harness the world's largest medicine cabinet with digital and other technology platforms to find ways of directing targeted drug development and creating patient-support programs that could make tangible improvements to this issue,” commented Iris Beck-Codner, Group Executive Vice President, Corporate Marketing & Communications, Teva, and panel co-chair.
Meeting participants ranging from the NCD Alliance (Non-Communicable Diseases), IBM Watson, patient advocacy organizations and leading public health experts, warned that the health care system is ill-equipped to deal with the rising burden:
The experts have pledged to identify key targets to help tackle this growing issue. Such targets will be aligned with the United Nations’ Sustainable Development Goal to ‘ensure health and well-being for all, at every stage of life’, and discussed at a follow-on meeting scheduled to take place later this year.
Cancer, heart disease, obesity, aging, dementia, depression… It's not just one illness we need to focus on, but all of them together – Teva is committed to seek solutions for patients with multiple chronic conditions (polychronic)
Through our expertise and influence, Teva is uniquely suited to lead a global effort to address polychronic diseases. Together, we will develop solutions that deliver lasting economic, societal and social impact to fulfil Teva's promise of creating better days for patients across the globe.